Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.39 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754886 | 0.77 | LMNA (0.47) | SLC9A1SLC9A2TRPV4ALDH1A1HPGD | |
| SCHEMBL25759561 | 0.77 | GLO1 (0.38) | TRPV4ALDH1A1 | |
| SCHEMBL1929488 | 0.77 | TRPV4 (0.44) | SLC9A1SLC9A2TRPV4ALDH1A1HPGD | |
| SCHEMBL25759570 | 0.75 | L3MBTL1 (0.39) | SLC9A1SLC9A2TRPV4ALDH1A1HPGD | |
| SCHEMBL25759566 | 0.73 | TSHR (0.33) | TRPV4ALDH1A1HPGD | |
| SCHEMBL21538604 | 0.72 | LMNA (0.40) | SLC9A1SLC9A2ALDH1A1HPGD | |
| SCHEMBL30534761 | 0.71 | TRPV4 (0.37) | SLC9A1TRPV4ALDH1A1FABP3FABP4 | |
| SCHEMBL7027875 | 0.71 | TRPV4 (0.37) | SLC9A1TRPV4ALDH1A1FABP3FABP4 | |
| SCHEMBL3971731 | 0.71 | ACE2 (0.50) | SLC9A1SLC9A2NPSR1 | |
| SCHEMBL31587739 | 0.71 | ACE2 (0.50) | SLC9A1SLC9A2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | SLC9A1 1050/4885SLC9A2 2907/4885TRPV4 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.